Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 7:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bioequivalence Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452

NCT05722262
View directory record Official record
Conditions
Healthy
Interventions
K-001, K-877-ER, CSG452
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Oxandrolone Tablets Under Fasting Conditions

NCT00652886
View directory record Official record
Conditions
To Determine the Bioequivalence Under Fasting Conditions
Interventions
Oxandrolone, Oxandrin
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Sep 16, 2026, 7:56 PM EDT
Not listed Phase 1 Interventional

A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer

NCT01715168
View directory record Official record
Conditions
Ovarian Cancer, Malignant Female Reproductive System Neoplasm, Cancer, Ovarian Tumor, Ovarian Epithelial Cancer Recurrent
Interventions
DOXIL/CAELYX, ATI-0918
Drug
Lead sponsor
Azaya Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Yakima, Washington
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

NCT02791308
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream 1% (Valeant), Vehicle cream, Pimecrolimus Cream, 1%
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 90 Years
Enrollment
587 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

NCT04890106
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Drug
Lead sponsor
Mankind Pharma Limited
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Bakersfield, California • Mission Hills, California • Newport Beach, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet

NCT00917644
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Atorvastatin
Drug · Genetic
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules

NCT04967443
View directory record Official record
Conditions
Hypertension, Heart Failure
Interventions
Prazosin HCl 2mg, Prazosin HCl 1 mg, Prazosin HCl 5 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Of Pediatric Appropriate Formulation

NCT00758004
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Atorvastatin pediatric appropriate formulation
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule

NCT04768985
View directory record Official record
Conditions
Bioequivalence
Interventions
Treatment A: Acalabrutinib tablet, Treatment B: Acalabrutinib capsule
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Glendale, California • Brooklyn, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg

NCT00649714
View directory record Official record
Conditions
Healthy
Interventions
Zonisamide Capsules 100 mg, Zonegran® Capsules 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

NCT02498418
View directory record Official record
Conditions
Diarrhea
Interventions
Rifaximin, Xifaxan®, Placebo Tablet
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg

NCT00647660
View directory record Official record
Conditions
Healthy
Interventions
Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg, Corzide® Tablets 80 mg/5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions

NCT00830206
View directory record Official record
Conditions
Healthy
Interventions
Azithromycin, Zithromax®
Other · Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Nicotine Lozenge Bioequivalence Study

NCT01536704
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine (2 mg), Nicotine (4 mg)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Formulations of Ixekizumab in Healthy Participants

NCT04259346
View directory record Official record
Conditions
Healthy
Interventions
Ixekizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Daytona Beach, Florida • Miami, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)

NCT01870986
View directory record Official record
Conditions
Healthy
Interventions
PF-06410293, Humira (adalimumab-EU), Humira (adalimumab-US)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cefprozil for Oral Suspension 250 mg/5 mL, Fasting

NCT00835614
View directory record Official record
Conditions
Healthy
Interventions
Cefprozil for oral suspension 250 mg/5 mL, CEFZIL® for Oral Suspension 250 mg/5mL
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
2
States / cities
Saint Charles, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions

NCT00834639
View directory record Official record
Conditions
Healthy
Interventions
divalproex sodium, Depakote®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg

NCT00648583
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron Tablets 24 mg, Zofran® Tablets 24 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream

NCT04358770
View directory record Official record
Conditions
Bioequivalence Study
Interventions
Clocortolone Pivalate
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Glimepiride 1mg Tablets Under Fed Conditions

NCT00776620
View directory record Official record
Conditions
Healthy
Interventions
Glimepiride 1mg Tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

NCT02073227
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg, CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions

NCT01591889
View directory record Official record
Conditions
Trichomoniasis
Interventions
Tinidazole
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 16, 2026, 7:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145

NCT02307461
View directory record Official record
Conditions
Healthy
Interventions
IPI-145 (duvelisib), IPI-145
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years to 50 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 16, 2026, 7:56 PM EDT